Epoprostenol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Epoprostenol: From Pulmonary Arterial Hypertension to Trigeminal Autonomic Cephalalgia
One-Sentence Summary
Epoprostenol is a prostacyclin (PGI2) vasodilator, originally used mainly for pulmonary arterial hypertension. The TxGNN model predicts it may be effective for trigeminal autonomic cephalalgia, but 0 clinical trials and 0 publications support this prediction. The related migraine literature suggests epoprostenol may provoke headache rather than relieve it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pulmonary arterial hypertension (taken from the knowledge-graph indication list, because the Singapore licence records do not state an indication) |
| Predicted New Indication | Trigeminal autonomic cephalalgia |
| TxGNN Prediction Score | 98.41% |
| Evidence Level | L5 (model prediction only) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, epoprostenol is a synthetic form of prostacyclin (PGI2). It is a potent vasodilator, and its efficacy in pulmonary arterial hypertension is established. Cranial vasodilation has been implicated in trigeminal autonomic cephalalgias, which is a possible reason the model links the drug to this condition.
On closer inspection, the biological reasoning points the other way. A study of intravenous epoprostenol in people with migraine (PMID 19614689) reported that it triggered migraine-like attacks. PGI2 is also known to activate and sensitise meningeal sensory nerve fibres. A therapeutic effect in headache disorders is therefore biologically implausible, and a safety signal is more likely. The high score probably reflects network proximity to PGI2 vasodilatory pathways, not evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for this specific indication.
The closest related work concerns headache in general. A 2010 provocation study (Cephalalgia, PMID 19614689) found that epoprostenol triggers migraine-like attacks in migraineurs. This is evidence of harm potential, not of therapeutic benefit.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN15405P | VELETRI Powder for Solution for Infusion 0.5 mg/vial | Injection, powder, for solution |
| SIN02241P | FLOLAN for Infusion 0.5 mg/vial | Injection, powder, for solution |
| SIN15406P | VELETRI Powder for Solution for Infusion 1.5 mg/vial | Injection, powder, for solution |
All three licences are valid single-ingredient products, and none has been cancelled. The approved indication text is not listed in the registration records. All products are injectable only, so the route may be a limitation for any new indication.
Safety Considerations
- Contraindications flagged in the knowledge graph (not taken from label text): blood coagulation disease and pulmonary edema.
- Drug Interactions: 100 interactions were identified. The 20 reviewed include these moderate-level ones:
- Epinephrine and ephedrine (including nasal ephedrine)
- Acetylsalicylic acid (aspirin)
- SGLT2 inhibitors: canagliflozin, dapagliflozin, empagliflozin and ertugliflozin
- Mannitol and glycerin
- Papaverine
- Fenfluramine, dexfenfluramine and sibutramine
- Interactions with pantoprazole, glimepiride, mesalazine, morphine, metformin and omeprazole are listed with an unknown severity level.
- Headache provocation by epoprostenol is a specific safety concern for this proposed use.
For label warnings, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone, with no trials or publications. The available mechanistic data suggest epoprostenol induces headache, so a benefit in trigeminal autonomic cephalalgia is unlikely and a safety signal is more plausible.
To proceed, the following is needed:
- Mechanism of action data and the package insert warnings and contraindications
- Preclinical or clinical evidence that prostacyclin agonism relieves, rather than provokes, trigeminal autonomic headache
- An assessment of whether an injectable-only product is practical for this condition
Note on other predictions: Among the other predicted indications, respiratory failure (score 77.7%, evidence level L3) has the most support. It is backed by one small completed Phase 4 study (n=14, inhaled prostacyclin after cardiac surgery) and several observational studies of inhaled epoprostenol. Its recommendation is "Research Question". It would be a more evidence-supported candidate for further evaluation, although no Phase 3 RCT evidence was identified and severe bronchospasm has been reported with inhaled prostacyclin.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.